ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib is a BCR-ABL kinase inhibitor which blocks the growth of BCR-ABL-transformed cells, and is effective in disease remission in chronic phase CML patients [6-8].